Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS.
Renaud La Joie, Ganna Blazhenets, Piyush Maiti, Konstantinos Chiotis, Ani Eloyan, Kala Kirby, Dustin Hammers, Robert A Koeppe, Sarah F Ackley, Justin Robison and 6 more
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Renaud La JoieEdward and Pearl Fein Memory and Aging Center UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco California USA.
Ganna BlazhenetsEdward and Pearl Fein Memory and Aging Center UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco California USA.
Piyush MaitiEdward and Pearl Fein Memory and Aging Center UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco California USA.
Konstantinos ChiotisEdward and Pearl Fein Memory and Aging Center UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco California USA.
Ani EloyanDepartment of Biostatistics Center for Biostatistics and Health Data Science, Brown University School of Public Health Providence Rhode Island USA.
Kala KirbyDepartment of Neurology Indiana University School of Medicine Indianapolis Indiana USA.
Dustin HammersDepartment of Neurology Indiana University School of Medicine Indianapolis Indiana USA.
Robert A KoeppeDepartment of Radiology University of Michigan Ann Arbor Michigan USA.
Sarah F AckleyDepartment of Epidemiology Brown University Providence Rhode Island USA.
Justin RobisonAlzheimer's Therapeutic Research Institute University of Southern California San Diego California USA.
David N Soleimani-MeigooniEdward and Pearl Fein Memory and Aging Center UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco California USA.
Maria C CarrilloMedical & Scientific Relations Division Alzheimer's Association Chicago Illinois USA.
Bradford C DickersonDepartment of Neurology Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA.
Liana G ApostolovaDepartment of Neurology Indiana University School of Medicine Indianapolis Indiana USA.
Gil D RabinoviciEdward and Pearl Fein Memory and Aging Center UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco California USA.
LEADS consortium
Funding
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2020 to 2026
$29.0M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Lisa Goldman Rosas · 2020 to 2026
$29.0M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROBERT J VASSAR · 2021 to 2026
introductionAs amyloid-targeting therapies (ATTs) enter clinical care, observational cohorts must accurately ascertain ATT exposure. We developed an approach to flag mis/undocumented ATT in the Longitudinal Early-Onset Alzheimer's Disease Study using longitudinal amyloid positron emission tomography (PET).
methodsWe analyzed 742 [
resultsPre-FDA approval segments increased by a median of 4.1 CL/year (whole cerebellum reference) and 3.6 CL/year (composite reference); unusual CL decline thresholds, defined as mean - 2 standard deviations of the pre-approval distributions were -15.8 and -9.4 CL/year, respectively. When applied to segments acquired post-FDA approval, extreme declines were observed in 59% to 78% of treated ( DISCUSSION: Longitudinal amyloid PET analyses can help identify ATT exposure in observational studies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS. · full record | OpenQuestion